Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Amortization of Deferred Charges (2024 - 2025)

Arrowhead Pharmaceuticals (ARWR) has disclosed Amortization of Deferred Charges for 2 consecutive years, with $14.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Amortization of Deferred Charges fell 8.17% year-over-year to $14.9 million, compared with a TTM value of $62.0 million through Dec 2025, up 142.68%, and an annual FY2025 reading of $63.3 million, up 579.67% over the prior year.
  • Amortization of Deferred Charges was $14.9 million for Q4 2025 at Arrowhead Pharmaceuticals, up from $14.6 million in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $16.4 million in Q2 2025 and bottomed at $9.3 million in Q3 2024.